JP6284546B2 - Ｃｆｔｒチャネルを阻害するための三環式化合物 - Google Patents

Ｃｆｔｒチャネルを阻害するための三環式化合物 Download PDF

Info

Publication number
JP6284546B2
JP6284546B2 JP2015548837A JP2015548837A JP6284546B2 JP 6284546 B2 JP6284546 B2 JP 6284546B2 JP 2015548837 A JP2015548837 A JP 2015548837A JP 2015548837 A JP2015548837 A JP 2015548837A JP 6284546 B2 JP6284546 B2 JP 6284546B2
Authority
JP
Japan
Prior art keywords
dimethyl
dione
pyrimido
pyrrolo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015548837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509579A5 (enExample
JP2016509579A (ja
Inventor
アーメッド，マバブ
アッシュオール‐ケリー，アレクサンダー
グエリツ，ルイーザ
マッケナ，ジェフリー
マッケナ，ジョセフ
ムトン，シモン
パーマー，ラケシ
シェーパード，ジョン
ライト，ポール
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6284546(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016509579A publication Critical patent/JP2016509579A/ja
Publication of JP2016509579A5 publication Critical patent/JP2016509579A5/ja
Application granted granted Critical
Publication of JP6284546B2 publication Critical patent/JP6284546B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015548837A 2012-12-19 2013-12-17 Ｃｆｔｒチャネルを阻害するための三環式化合物 Expired - Fee Related JP6284546B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US61/739,335 2012-12-19
US201361906141P 2013-11-19 2013-11-19
US61/906,141 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (3)

Publication Number Publication Date
JP2016509579A JP2016509579A (ja) 2016-03-31
JP2016509579A5 JP2016509579A5 (enExample) 2017-01-26
JP6284546B2 true JP6284546B2 (ja) 2018-02-28

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548837A Expired - Fee Related JP6284546B2 (ja) 2012-12-19 2013-12-17 Ｃｆｔｒチャネルを阻害するための三環式化合物

Country Status (25)

Country Link
US (2) US9359381B2 (enExample)
EP (1) EP2935278B1 (enExample)
JP (1) JP6284546B2 (enExample)
KR (1) KR20150097660A (enExample)
CN (1) CN105143230B (enExample)
AP (1) AP2015008539A0 (enExample)
AR (1) AR094122A1 (enExample)
AU (1) AU2013365739A1 (enExample)
BR (1) BR112015014292A2 (enExample)
CA (1) CA2895660A1 (enExample)
CL (1) CL2015001730A1 (enExample)
CR (1) CR20150325A (enExample)
CU (1) CU20150066A7 (enExample)
EA (1) EA201591177A1 (enExample)
ES (1) ES2628369T3 (enExample)
HK (1) HK1209741A1 (enExample)
IL (1) IL239389A0 (enExample)
MX (1) MX2015007939A (enExample)
PE (1) PE20151055A1 (enExample)
PH (1) PH12015501386A1 (enExample)
SG (1) SG11201504594QA (enExample)
TN (1) TN2015000279A1 (enExample)
TW (1) TW201429974A (enExample)
UY (1) UY35211A (enExample)
WO (1) WO2014097148A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
EP2935278B1 (en) 2012-12-19 2017-03-15 Novartis AG Tricyclic compounds for inhibiting the cftr channel
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
CN106715536B (zh) * 2014-09-19 2021-06-01 莫门蒂夫性能材料股份有限公司 用于受控的硅氧烷交联的铂(ii)二烯配合物
US9624233B2 (en) * 2015-04-23 2017-04-18 Trevi Therapeutics, Inc. Compounds for treating pruritic conditions
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
CN114007623A (zh) * 2019-06-12 2022-02-01 加利福尼亚大学董事会 治疗胆汁酸性腹泻的方法
AU2022265718A1 (en) 2021-04-29 2023-11-02 Novartis Ag Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382528A1 (en) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
IN2012DN00719A (enExample) * 2009-08-10 2015-06-19 Univ California
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2935278B1 (en) 2012-12-19 2017-03-15 Novartis AG Tricyclic compounds for inhibiting the cftr channel
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물

Also Published As

Publication number Publication date
HK1209741A1 (en) 2016-04-08
US9359381B2 (en) 2016-06-07
KR20150097660A (ko) 2015-08-26
IL239389A0 (en) 2015-07-30
ES2628369T3 (es) 2017-08-02
WO2014097148A9 (en) 2015-02-19
TW201429974A (zh) 2014-08-01
EP2935278B1 (en) 2017-03-15
CN105143230A (zh) 2015-12-09
CL2015001730A1 (es) 2015-08-28
AU2013365739A1 (en) 2015-07-09
EP2935278A1 (en) 2015-10-28
TN2015000279A1 (en) 2016-10-03
CN105143230B (zh) 2017-06-09
CA2895660A1 (en) 2014-06-26
EA201591177A1 (ru) 2015-11-30
UY35211A (es) 2014-07-31
CR20150325A (es) 2015-08-10
JP2016509579A (ja) 2016-03-31
PH12015501386A1 (en) 2015-09-02
BR112015014292A2 (pt) 2017-07-11
US20140171417A1 (en) 2014-06-19
PE20151055A1 (es) 2015-08-05
SG11201504594QA (en) 2015-07-30
AP2015008539A0 (en) 2015-06-30
MX2015007939A (es) 2016-03-11
CU20150066A7 (es) 2015-11-27
US20150336986A1 (en) 2015-11-26
AR094122A1 (es) 2015-07-08
WO2014097148A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
JP6284546B2 (ja) Ｃｆｔｒチャネルを阻害するための三環式化合物
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
TWI468402B (zh) 降低β－類澱粉生成之化合物
JP6284545B2 (ja) Ｃｆｔｒ阻害としての三環式化合物
TW201900640A (zh) 作為irak4抑制劑之噻吩并吡啶及苯并噻吩
EP3055315B1 (en) Thiazolopyrimidinones as modulators of nmda receptor activity
US20140200344A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
TW200813064A (en) Purinone derivatives as HM74A agonists
KR20210095143A (ko) Hbv의 치료를 위한 5원 헤테로아릴 카르복스아미드 화합물
CN110156813A (zh) 作为trk抑制剂的杂环化合物
TW202128699A (zh) 治療性化合物
US20250282799A1 (en) SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS
TW202513063A (zh) 用於治療癌症及其他適應症之稠合吡啶
JP7091455B2 (ja) ピリジノン誘導体及びそれらの選択的ａｌｋ－２阻害剤としての使用
JP2023504862A (ja) ブルトン型チロシンキナーゼ阻害剤としてのイミダゾールカルボキサミド誘導体
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
CN103492390A (zh) 氟苯基双环杂芳基化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180130

R150 Certificate of patent or registration of utility model

Ref document number: 6284546

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees